Skip to content
DataLookout
Menu

BELASBRIDGENCT05562869

Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from May 3, 2027 to Nov 3, 2028
    • Eligibility criteria expanded, about 21 words
    • Publications: details revised at 2 of 2 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Sep 9, 2024 to May 3, 2027
    • Start date changed from estimate of Nov 1, 2022 to May 3, 2024
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Feasibility of a transient replacement of CNIs by belatacept in renal transplant patients with early graft dysfunction. Creatinine clearance did not decrease by more than 25% from the cessation of belatacept 6 months after reintroduction of CNI.
Timeframe: Month 15

Secondary (6)

Evaluate the effectiveness of belatacept treatment on renal function (creatinine clairance) and to prevent rejection. (Number of rejection épisodes)
Evaluate the tolerance of treatments (belatacept during phase 1 and CNI during phase 2). Number of adverse events.
Estimate the cost of care (from 3 months to 18 months post-transplant) and compare with the cost of a theoretical arm benefiting from belatacept continuously and a theoretical arm benefiting from CNIs continuously.
Evaluate the evolution of the quality of life during the 15 months of follow-up and compare it to a theoretical arm benefiting from belatacept continuously, and a theoretical arm benefiting from CNIs continuously: generic EuroQol-5D scale
Evaluate the differential impact of SNFs and belatacept on cell populations of the immune system
Show 1 moreShow less
Evaluate the differential impact of NICs and belatacept on the level of CMV replication and its clinical consequences.

Arms and interventions

Experimental: transient belataceptExperimental

IV, 5mg/Kg days 1, 15, 30, 45 and 60 then every months

Drugs: Belatacept 250 Milligram Intravenous Powder for Solution

Sites

1 site in 1 country

  • CHU NantesNantes, Loire Atlantique, France